Catenacci, D. V. T., Park, H., Uronis, H. E., Kang, Y.-K., Lacy, J., Enzinger, P. C., … Bang, Y.-J. (2018). Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). In Journal of Clinical Oncology (Vol. 36, pp. 4030–4030). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.4030

Catenacci, Daniel V. T., Haeseong Park, Hope Elizabeth Uronis, Yoon-Koo Kang, Jill Lacy, Peter C. Enzinger, Se Hoon Park, et al. “Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).” In Journal of Clinical Oncology, 36:4030–4030. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4030.

Catenacci DVT, Park H, Uronis HE, Kang Y-K, Lacy J, Enzinger PC, et al. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4030–4030.

Catenacci, Daniel V. T., et al. “Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 4030–4030. Crossref, doi:10.1200/jco.2018.36.15_suppl.4030.

Catenacci DVT, Park H, Uronis HE, Kang Y-K, Lacy J, Enzinger PC, Park SH, Lee KW, Ng MCH, Gold PJ, Yen J, Franovic A, Kelly RJ, Wynter-Horton A, Li D, Muth J, Baughman JE, Hong S, Davidson-Moncada JK, Bang Y-J. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4030–4030.